Researchers in Germany are pioneering a novel perfusion process aimed at enhancing the manufacture of oncolytic viruses. The team at the Max Planck Institute is focused on improving virus yields while simultaneously promoting sustainability in bioprocesses, ultimately benefiting patients with more effective therapies.
Challenges of Traditional Manufacturing
Oncolytic virus therapies represent a promising avenue for cancer treatment; however, they require substantial input doses. Lennart Jacobtorweihe, a doctoral researcher in upstream processing at the Max Planck Institute, highlights the limitations of current manufacturing practices. Traditional batch processes, often reliant on adherent cell cultures, fall short in achieving the necessary virus titers.
The Shift to Perfusion Processes
To address these challenges, the research team has developed perfusion methods utilizing suspension cells. These processes are specifically designed to generate various types of oncolytic viruses at elevated cell concentrations while preserving the productivity characteristics typical of batch processing.
Addressing Short Half-Life Issues
Perfusion technology is not new to bioprocess engineering; however, the unique properties of oncolytic viruses complicate continuous manufacturing. Jacobtorweihe notes that these viruses often possess a half-life of just a few hours at standard incubation temperatures of 33–37°C. To mitigate this issue during a four-day production cycle, the researchers implemented advanced technologies, including a tangential flow depth filtration system from Repligen. This system allows for simultaneous harvesting and cooling of viruses throughout manufacturing, significantly reducing losses compared to conventional batch methods.
Optimizing Process Parameters
The Max Planck team further customized their approach by adjusting stirring speeds, temperatures, and multiplicity of infection tailored to various oncolytic viruses and their specific cell substrates. Jacobtorweihe emphasizes the need for versatility in treatment approaches, stating that “each virus is not a copy-paste of what was developed and published before.” This adaptability is crucial in addressing the diverse landscape of cancer therapies.
Exploring New Frontiers
The researchers are now progressing to test additional virus types, with a goal of increasing cell concentrations from the current 20 million cells per milliliter to approximately 100 million cells. Jacobtorweihe articulates their aspiration to explore the limits of cell retention and viral processes, aiming for a five-fold increase in virus titer.
Future Implications
The implications of these advancements could be significant for the field of oncology. Enhanced manufacturing processes may lead to more accessible and effective oncolytic virus therapies, ultimately improving patient outcomes. Such developments represent a crucial step in the evolution of biotherapeutics, combining rigorous scientific inquiry with innovative engineering solutions.
Key Takeaways
- Researchers at the Max Planck Institute are enhancing oncolytic virus production through a novel perfusion process.
- Traditional batch processes limit virus titers, prompting the shift to suspension cell perfusion methods.
-
Advanced filtration technologies help mitigate the short half-life of oncolytic viruses during manufacturing.
-
The team is exploring higher cell concentrations and diverse virus types to optimize production.
In conclusion, the innovative perfusion strategies being developed for oncolytic virus manufacturing could reshape the landscape of cancer treatment. By addressing existing challenges in production and focusing on patient outcomes, this research holds the potential to unlock new therapeutic avenues and significantly impact the future of oncology.
Read more → www.genengnews.com